Barclays’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-5,200
| Closed | -$795K | – | 5171 |
|
|
2021
Q1 | $795K | Sell |
5,200
-11,200
| -68% | -$1.73M | ﹤0.01% | 2912 |
|
|
2020
Q4 | $2.56M | Buy |
16,400
+15,000
| +1,071% | +$1.93M | ﹤0.01% | 2046 |
|
|
2020
Q3 | $160K | Sell |
1,400
-166,400
| -99% | -$18M | ﹤0.01% | 3992 |
|
|
2020
Q2 | $18.8M | Sell |
167,800
-93,300
| -36% | -$9.91M | 0.01% | 667 |
|
|
2020
Q1 | $23.4M | Buy |
261,100
+195,900
| +300% | +$19.2M | 0.02% | 572 |
|
|
2019
Q4 | $7.05M | Sell |
65,200
-30,000
| -32% | -$3.21M | ﹤0.01% | 1677 |
|
|
2019
Q3 | $9.32M | Buy |
95,200
+35,500
| +59% | +$4M | 0.01% | 1336 |
|
|
2019
Q2 | $7.82M | Sell |
59,700
-98,900
| -62% | -$12.7M | ﹤0.01% | 1518 |
|
|
2019
Q1 | $21.4M | Sell |
158,600
-5,400
| -3% | -$671K | 0.01% | 814 |
|
|
2018
Q4 | $16M | Buy |
164,000
+91,400
| +126% | +$10.8M | 0.01% | 873 |
|
|
2018
Q3 | $10.1M | Sell |
72,600
-106,700
| -60% | -$13.4M | 0.01% | 1253 |
|
|
2018
Q2 | $22.3M | Buy |
179,300
+40,900
| +30% | +$4.78M | 0.02% | 739 |
|
|
2018
Q1 | $15.4M | Buy |
138,400
+19,100
| +16% | +$2.28M | 0.01% | 979 |
|
|
2017
Q4 | $14.3M | Sell |
119,300
-42,400
| -26% | -$5.16M | 0.01% | 985 |
|
|
2017
Q3 | $22.7M | Sell |
161,700
-161,800
| -50% | -$22M | 0.02% | 608 |
|
|
2017
Q2 | $39.4M | Sell |
323,500
-88,400
| -21% | -$10.3M | 0.04% | 355 |
|
|
2017
Q1 | $49.9M | Buy |
411,900
+312,200
| +313% | +$40.3M | 0.05% | 250 |
|
|
2016
Q4 | $12.2M | Buy |
99,700
+51,100
| +105% | +$6.25M | 0.01% | 837 |
|
|
2016
Q3 | $5.96M | Buy |
48,600
+25,300
| +109% | +$3.26M | 0.01% | 1166 |
|
|
2016
Q2 | $2.72M | Sell |
23,300
-99,700
| -81% | -$14.1M | ﹤0.01% | 1762 |
|
|
2016
Q1 | $17.1M | Buy |
123,000
+86,600
| +238% | +$12.7M | 0.03% | 534 |
|
|
2015
Q4 | $6.92M | Buy |
36,400
+16,000
| +78% | +$2.79M | 0.01% | 1092 |
|
|
2015
Q3 | $3.18M | Buy |
20,400
+4,200
| +26% | +$766K | ﹤0.01% | 1719 |
|
|
2015
Q2 | $2.92M | Sell |
16,200
-9,000
| -36% | -$1.55M | ﹤0.01% | 1916 |
|
|
2015
Q1 | $4.36M | Sell |
25,200
-13,300
| -35% | -$2.41M | 0.01% | 1671 |
|
|
2014
Q4 | $7.12M | Buy |
38,500
+10,200
| +36% | +$1.89M | 0.01% | 1419 |
|
|
2014
Q3 | $4.67M | Buy |
28,300
+9,900
| +54% | +$1.63M | ﹤0.01% | 1849 |
|
|
2014
Q2 | $2.87M | Sell |
18,400
-268,800
| -94% | -$42.4M | ﹤0.01% | 2258 |
|
|
2014
Q1 | $43.7M | Sell |
287,200
-119,400
| -29% | -$19M | 0.05% | 340 |
|
|
2013
Q4 | $53.7M | Buy |
406,600
+77,500
| +24% | +$9.3M | 0.06% | 314 |
|
|
2013
Q3 | $38.2M | Buy |
329,100
+218,800
| +198% | +$24M | 0.05% | 379 |
|
|
2013
Q2 | $10.2M | Buy |
+110,300
| New | +$10.6M | 0.01% | 1058 |
|
Other funds holding ALXN
Barclays's ALXN Position: Q4 2021 in Review
Barclays sold out of Alexion Pharmaceuticals (ALXN) in Q4 2021, closing a stake of 6 shares — an estimated $22K sold.
Barclays first reported a position in ALXN in Q2 2013 and held it in 34 quarters. The position peaked at $547M in Q1 2021. 2 funds tracked by Wall St. Rank hold ALXN as of Q4 2021.
- Barclays reported no remaining Alexion Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Barclays sold 6 Alexion Pharmaceuticals shares in Q4 2021, an estimated $22K.
- Barclays first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 34 quarters.
- Barclays's Alexion Pharmaceuticals position peaked at $547M in Q1 2021.
- 2 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2021.
Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.